Studies have shown that thymoquinone, an inhibitor of the Akt/mTOR/S6 pathway, not only enhances the sensitivity of oxaliplatin and cisplatin in pancreatic cancer but also similarly promotes sensitivity to gemcitabine [39]. Here, AKT1 is linked to pancreatic neoplasm.